在GOLD组B或D患者中,LABA/LAMA何时比LAMA更好,以减少COPD的急性恶化?
Hong-Joon Shin1, Yu-Il Kim1, Youlim Kim2
1Division of Pulmonary Medicine, Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea.
Chonnam medical journal
|October 16, 2023
概括
与LAMA单疗法相比,长期作用的β2激动剂/长期作用的肌肉激动剂-对抗剂 (LABA/LAMA) 双重治疗显著减少了COPD患者的急性恶化. 这种益处在患有B组COPD和D组严重症状的老年人中尤为明显.
科学领域:
- 肺部病理学 肺部病理学
- 呼吸系统医学 呼吸系统医学
- 药物治疗 药物治疗
背景情况:
- 长效β2激动剂 (LABA) /长效肌激动剂-对抗剂 (LAMA) 双重治疗因其在治疗慢性阻塞性肺病 (COPD) 的有效性而得到认可.
- 在全球慢性阻塞性肺病倡议 (GOLD) 组B和D中,针对LABA/LAMA双重疗法在减少急性恶化方面提供比LAMA单一疗法更好的好处的特定患者子组仍然不完全理解.
- 识别这些特征对于优化COPD治疗策略和尽量减少疾病恶化至关重要.
研究的目的:
- 调查LABA/LAMA双疗法与LAMA单疗法在减少B组和D组COPD患者急性恶化中的比较有效性.
- 为了确定B组和D组内的特定患者特征,预测LABA/LAMA双重治疗在预防恶化方面具有更大的益处.
主要方法:
- 一项前性队列研究涉及737名被诊断为B组 (n=600) 或D组 (n=137) COPD的患者,根据2022年GOLD指南进行分类.
- 患者接受了LAMA单疗法或LABA/LAMA双疗法.
- 进行了子组分析,以评估1年内急性恶化的发生率,重点关注年龄和COPD评估测试 (CAT) 成绩.
主要成果:
- 接受LABA/LAMA双重治疗的患者,与接受LAMA单一治疗一年的患者相比,急性恶化发生率显著降低.
- 在70岁以上的B组COPD患者中,LABA/LAMA治疗与LAMA单独治疗相比,严重恶化的风险明显降低 (OR,0.258;95% CI,0.095-0.703).
- 在CAT分数≥25的D组COPD患者中,LABA/LAMA治疗与LAMA单疗相比显著降低了严重恶化的风险 (OR,0.115;95%CI,0.018-0.749).
结论:
- 在降低B组和D组COPD患者急性恶化方面,LABA/LAMA双疗优于LAMA单疗.
- LABA/LAMA双重治疗的益处对于患有B组COPD的老年人 (≥70岁) 和出现严重症状的D组患者 (CAT评分≥25) 尤其显著.
- 这些发现支持在特定的COPD患者个人资料中量身定制使用LABA/LAMA双疗法,以加强恶化预防.
更多相关视频
00:07Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
9.7K
05:19Author Spotlight: An Effective Traditional Chinese Medicinal Treatment for Chronic Obstructive Pulmonary Disease with Abdominal Distension
Published on: September 1, 2023
1.5K
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
218
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
218
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
278
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
278
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:17Drugs Used in Lower Respiratory Disorders: Overview
462
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
462
01:19Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324